VanEck Associates
AZN icon

VanEck Associates’s AstraZeneca AZN Stock Holding History

VanEck Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54.5M Sell
276,361
-30,345
-10% -$5.85M 0.04% 258
2025
Q4 		$56.4M Buy
306,706
+151,486
+98% +$26.6M 0.05% 235
2025
Q3 		$23.8M Sell
155,220
-36,404
-19% -$5.51M 0.02% 326
2025
Q2 		$26.8M Sell
191,624
-29,844
-13% -$4.18M 0.03% 299
2025
Q1 		$32.6M Sell
221,468
-8,312
-4% -$1.2M 0.04% 246
2024
Q4 		$30.1M Buy
229,780
+7,384
+3% +$1.03M 0.04% 249
2024
Q3 		$34.2M Buy
222,396
+33,501
+18% +$5.41M 0.04% 224
2024
Q2 		$29.5M Sell
188,895
-21,760
-10% -$3.27M 0.04% 220
2024
Q1 		$28.5M Buy
210,655
+49,418
+31% +$6.54M 0.04% 222
2023
Q4 		$21.7M Buy
161,237
+442
+0.3% +$57.5K 0.04% 230
2023
Q3 		$21.8M Buy
160,795
+32,577
+25% +$4.45M 0.05% 226
2023
Q2 		$18.4M Sell
128,218
-11,277
-8% -$1.66M 0.04% 259
2023
Q1 		$19.4M Sell
139,495
-72,114
-34% -$9.7M 0.04% 245
2022
Q4 		$28.7M Sell
211,609
-18,559
-8% -$2.33M 0.07% 199
2022
Q3 		$25.2M Sell
230,168
-1,439
-0.6% -$183K 0.08% 195
2022
Q2 		$30.6M Buy
231,607
+82,370
+55% +$10.8M 0.08% 195
2022
Q1 		$19.8M Sell
149,237
-11,371
-7% -$1.36M 0.04% 250
2021
Q4 		$18.7M Buy
160,608
+15,005
+10% +$1.77M 0.04% 264
2021
Q3 		$17.5M Buy
145,603
+36,372
+33% +$4.23M 0.04% 264
2021
Q2 		$13.1M Sell
109,231
-13,468
-11% -$1.48M 0.03% 312
2021
Q1 		$12.2M Buy
122,699
+6,173
+5% +$621K 0.03% 308
2020
Q4 		$11.7M Buy
116,526
+6,410
+6% +$679K 0.03% 282
2020
Q3 		$12.1M Buy
110,116
+154
+0.1% +$17.1K 0.04% 238
2020
Q2 		$11.6M Buy
109,962
+5,641
+5% +$583K 0.04% 238
2020
Q1 		$9.32M Buy
104,321
+1,795
+2% +$169K 0.05% 232
2019
Q4 		$10.2M Buy
102,526
+18,875
+23% +$1.78M 0.04% 255
2019
Q3 		$7.46M Sell
83,651
-23,932
-22% -$2.08M 0.03% 265
2019
Q2 		$8.88M Sell
107,583
-3,187
-3% -$250K 0.04% 235
2019
Q1 		$8.96M Sell
110,770
-49,406
-31% -$3.89M 0.04% 227
2018
Q4 		$12.2M Sell
160,176
-17,743
-10% -$1.39M 0.06% 210
2018
Q3 		$14.1M Sell
177,919
-12,792
-7% -$968K 0.07% 213
2018
Q2 		$13.4M Buy
190,711
+5,015
+3% +$361K 0.06% 212
2018
Q1 		$13M Sell
185,696
-23,899
-11% -$1.66M 0.06% 216
2017
Q4 		$14.5M Sell
209,595
-16,818
-7% -$1.13M 0.07% 199
2017
Q3 		$15.3M Buy
226,413
+29,807
+15% +$1.88M 0.08% 200
2017
Q2 		$13.4M Sell
196,606
-86,264
-30% -$5.63M 0.07% 205
2017
Q1 		$17.6M Buy
282,870
+58,122
+26% +$3.38M 0.08% 177
2016
Q4 		$12.3M Buy
224,748
+44,454
+25% +$2.52M 0.06% 191
2016
Q3 		$11.8M Sell
180,294
-20,200
-10% -$1.32M 0.06% 188
2016
Q2 		$12.1M Buy
200,494
+1,353
+0.7% +$78.6K 0.06% 184
2016
Q1 		$11.2M Sell
199,141
-44,620
-18% -$2.68M 0.08% 163
2015
Q4 		$16.6M Buy
243,761
+12,421
+5% +$814K 0.13% 149
2015
Q3 		$14.7M Sell
231,340
-31,308
-12% -$2.06M 0.11% 154
2015
Q2 		$16.7M Buy
262,648
+34,592
+15% +$2.37M 0.1% 167
2015
Q1 		$15.6M Buy
228,056
+28,040
+14% +$1.95M 0.09% 172
2014
Q4 		$14.1M Sell
200,016
-41,747
-17% -$2.99M 0.09% 174
2014
Q3 		$17.3M Buy
241,763
+37,567
+18% +$2.75M 0.09% 160
2014
Q2 		$15.2M Sell
204,196
-8,755
-4% -$633K 0.07% 171
2014
Q1 		$13.8M Buy
212,951
+10,594
+5% +$684K 0.07% 169
2013
Q4 		$12M Sell
202,357
-11,374
-5% -$618K 0.06% 170
2013
Q3 		$11.1M Buy
213,731
+1,251
+0.6% +$62.8K 0.06% 164
2013
Q2 		$10.1M Buy
+212,480
New +$10.8M 0.05% 168

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $148B AUM

VanEck Associates's AZN Position: Q1 2026 in Review

VanEck Associates reduced its AstraZeneca (AZN) stake by 9.9% in Q1 2026, selling an estimated $5.85M and leaving 276,361 shares worth $54.5M. The position accounts for 0.04% of the portfolio, ranked #258.

VanEck Associates first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. The position peaked at $56.4M in Q4 2025. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • VanEck Associates held 276,361 shares of AstraZeneca worth $54.5M as of Q1 2026.
  • VanEck Associates sold 30,345 AstraZeneca shares in Q1 2026, an estimated $5.85M.
  • AstraZeneca made up 0.04% of VanEck Associates's portfolio in Q1 2026, its #258 holding.
  • VanEck Associates first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
  • VanEck Associates's AstraZeneca position peaked at $56.4M in Q4 2025.
  • 1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.